Skye Bioscience will present at two investor conferences focusing on obesity and metabolic health therapies.
Quiver AI Summary
Skye Bioscience, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for obesity and metabolic health disorders, announced its participation in two upcoming investor conferences. The first event is the BIO CEO & Investor Conference in New York on February 10, 2025, where Skye will discuss obesity treatment innovations. The second event is the Oppenheimer 35th Healthcare Life Sciences Conference, held virtually on February 12, 2025, where the company will present an overview of its operations. Skye is currently conducting a Phase 2 clinical trial on nimacimab, a treatment for obesity that works by inhibiting the CB1 receptor, and is also evaluating its combined use with the GLP-1R agonist Wegovy®. More information can be found on Skye's website.
Potential Positives
- Skye Bioscience is actively participating in significant investor conferences, increasing visibility and engagement with potential investors.
- The company is conducting a Phase 2 clinical trial for nimacimab, positioning itself in the promising market of obesity treatment with a focus on novel therapeutic pathways.
- Skye's approach to develop first-in-class therapeutics with substantial human proof of mechanism demonstrates a commitment to innovation and potential competitive differentiation.
- Accessibility of a live and archived webcast of the corporate overview may enhance investor communication and transparency, fostering trust and interest in the company.
Potential Negatives
- The mention of multiple risks and uncertainties in the forward-looking statements may create concerns about the company's ability to achieve its strategic goals.
- The company's focus on a narrow therapeutic area (obesity) in a highly competitive market could raise questions about its long-term viability and market position.
- The clinical trial involving nimacimab could face delays or obstacles, which may adversely affect investor confidence and stock performance.
FAQ
What is Skye Bioscience's focus as a company?
Skye Bioscience focuses on developing new therapeutic pathways for obesity and metabolic health disorders using next-generation molecules.
When will Skye participate in the BIO CEO & Investor Conference?
Skye will participate in the BIO CEO & Investor Conference on February 10, 2025, from 11:00 AM to 11:50 AM ET.
What is Skye's Phase 2 clinical trial about?
The Phase 2 clinical trial evaluates nimacimab, an antibody that inhibits CB1, for treating obesity and its combination with Wegovy®.
How can investors access Skye's corporate overview?
Investors can access Skye's corporate overview on February 12, 2025, via a live and archived webcast on Skye's website.
Where can I find more information about Skye Bioscience?
More information about Skye Bioscience can be found on their official website at www.skyebioscience.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SKYE Insider Trading Activity
$SKYE insiders have traded $SKYE stock on the open market 20 times in the past 6 months. Of those trades, 0 have been purchases and 20 have been sales.
Here’s a breakdown of recent trading of $SKYE stock by insiders over the last 6 months:
- ANDREW J. SCHWAB has made 0 purchases and 6 sales selling 266,337 shares for an estimated $1,750,352.
- PARTNERS VII, LLC 5AM has made 0 purchases and 6 sales selling 266,337 shares for an estimated $1,750,352.
- PAUL A. GRAYSON has made 0 purchases and 2 sales selling 86,551 shares for an estimated $432,061.
- PUNIT DHILLON (Chief Executive Officer) has made 0 purchases and 2 sales selling 82,910 shares for an estimated $413,924.
- KAITLYN ARSENAULT (Chief Financial Officer) has made 0 purchases and 2 sales selling 43,396 shares for an estimated $216,652.
- TUAN TU DIEP (Chief Development Officer) has made 0 purchases and 2 sales selling 19,574 shares for an estimated $97,721.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SKYE Hedge Fund Activity
We have seen 41 institutional investors add shares of $SKYE stock to their portfolio, and 18 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- LOGOS GLOBAL MANAGEMENT LP removed 1,201,518 shares (-92.3%) from their portfolio in Q3 2024, for an estimated $4,697,935
- BAKER BROS. ADVISORS LP added 934,634 shares (+186.9%) to their portfolio in Q3 2024, for an estimated $3,654,418
- JANUS HENDERSON GROUP PLC removed 905,650 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $3,541,091
- ENSIGN PEAK ADVISORS, INC added 900,000 shares (+inf%) to their portfolio in Q3 2024, for an estimated $3,519,000
- SCHONFELD STRATEGIC ADVISORS LLC added 527,742 shares (+122.3%) to their portfolio in Q3 2024, for an estimated $2,063,471
- PERCEPTIVE ADVISORS LLC removed 500,000 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $1,955,000
- PLATINUM INVESTMENT MANAGEMENT LTD added 485,199 shares (+inf%) to their portfolio in Q3 2024, for an estimated $1,897,128
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SAN DIEGO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will participate in the following investor conferences:
BIO CEO & Investor Conference
New York
Panel: Obesity: Next Medicines with Impact
Monday, February 10, 2025, 11:00 AM - 11:50 AM ET
Oppenheimer 35th Healthcare Life Sciences Conference
Virtual
Corporate overview
Wednesday, February 12th, 2025, at 12:00 PM - 12:30 PM ET
A live and archived webcast will be accessible on Skye’s
website
.
About Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial (
ClinicalTrials.gov: NCT06577090
) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit:
www.skyebioscience.com
. Connect with us on
X
and
LinkedIn
.
CONTACTS
Investor Relations
ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306
Media Inquiries
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(628) 234-3889
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “plans,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company’s periodic filings with the Securities and Exchange Commission, including in the “Risk Factors” section of Skye’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
